Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market

Executive Summary

After announcing the $13bn acquisition of Novartis' 36.5% share of their JV, GSK said its Horlicks nutritional beverage line and its consumer health subsidiary in India, the source of most Horlicks sales, are potential divestments. The firm also will consider selling other consumer health nutrition products.


Related Content

GSK Invests In OTC Production, Prepares To Divest Horlicks Nutritional Business
GSK Sees Excedrin Sales Growth As Consumers Visualize Headache Pain
Oral Care Drives OTC Sales As Glaxo Buffs Its Consumer Health Shine
Consumer Health Sector Holds Private Equity Investors' Attention
Consumer Health Sector Holds Private Equity Investors' Attention
GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes
Merck, Pfizer Decorate Consumer Health 'For Sale' Signs With Strong Results
GSK Trims Nutritional Drink Lines, Wants All Of Its Consumer JV Pie
Glaxo In Charge, And The World Is GSK/Novartis Consumer Product JV’s Oyster
Glaxo And Novartis Scratch Each Other’s Back With Consumer Product JV


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts